Those who have the ability to ignore the noise and the roller coaster ride that the markets have brought upon us from early October to this day, you would be +80% on $ARGX. Nevertheless, if you were/are trading/playing it, it's a good play.
Whether it's politics or economics, there's way too many factors in play so all things are considered, -awareness for the win.
Biotech wise, there are only few variables that I need to ponder here. Short float is at 2.84% because a convincing phase3 data on ARGX-113 for Myasthenia Gravis, will blow the shorts. Not to mention Cusatuzumab for acute myeloid leukemia. These are just 2 of the many 2019 catalysts.
Other key stats: 1) $500mm from the Janssen deal -$JNJ, 2) $10mm payment from Abbvie- (2018 preclinical milestone on ARGX-115), upon achievements of other milestones they're eligible for up to $625 million and double digit royalties upon commercialization.
Overweight on Morgan Stanley, Jan 4th, '19.
Buy on Goldman, Dec 17th, '18
Bottomline, I am watching this. You have to!
Whether it's politics or economics, there's way too many factors in play so all things are considered, -awareness for the win.
Biotech wise, there are only few variables that I need to ponder here. Short float is at 2.84% because a convincing phase3 data on ARGX-113 for Myasthenia Gravis, will blow the shorts. Not to mention Cusatuzumab for acute myeloid leukemia. These are just 2 of the many 2019 catalysts.
Other key stats: 1) $500mm from the Janssen deal -$JNJ, 2) $10mm payment from Abbvie- (2018 preclinical milestone on ARGX-115), upon achievements of other milestones they're eligible for up to $625 million and double digit royalties upon commercialization.
Overweight on Morgan Stanley, Jan 4th, '19.
Buy on Goldman, Dec 17th, '18
Bottomline, I am watching this. You have to!
交易進行:
Let's see.. I am long here at 103.47 on Jan 14th.
手動結束交易:
Closed. Will go in again later.
交易結束：目標達成